Letter to the Editor: Cilofexor in Patients With Nonalcoholic Steatohepatitis (NASH): Is It Really Effective?
Ankur Jindal, Shiv K. Sarin – 2 June 2020
Ankur Jindal, Shiv K. Sarin – 2 June 2020
Guadalupe García‐Tsao, Iaarah Montalvo‐Gordon – 2 June 2020
Leanne Thalji, Nassir M. Thalji, Julie K. Heimbach, Samar H. Ibrahim, Patrick S. Kamath, Andrew Hanson, Phillip J. Schulte, Dawit T. Haile, Daryl J. Kor – 2 June 2020
Sandra De Jonghe, Daniel Weinstock, Jason Aligo, Kay Washington, Dean Naisbitt – 2 June 2020
Sandra De Jonghe, Daniel Weinstock, Jason Aligo, Kay Washington, Dean Naisbitt – 2 June 2020
Sanjay Kumar Yadav, Narendr Singh Choudhary, Arvinder Singh Soin – 2 June 2020
Sami Akbulut, Tevfik Tolga Sahin, Cemalettin Koc, Sezai Yilmaz – 2 June 2020
Douglas Motomura, Tara Baetz, Andrea Grin, Jennifer A. Flemming – 2 June 2020
Xin Wang, Ling‐yue Dong, Qu‐jing Gai, Wei‐lun Ai, Yuan Wu, Wei‐chun Xiao, Jing Zhang, Wei An – 2 June 2020 – It is well known that excessive cholesterol accumulation within hepatocytes deteriorates nonalcoholic fatty liver disease (NAFLD). Augmenter of liver regeneration (ALR) has been reported to alleviate NAFLD through anti‐apoptosis; however, whether ALR could protect liver from cholesterol‐induced NAFLD remains unclear.
Douglas Motomura, Tara Baetz, Andrea Grin, Jennifer A. Flemming – 2 June 2020